A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Inclusion Criteria: * Dose determination cohorts: Histologically confirmed diagnosis of metastatic RCC of either clear cell or non-clear histology. * Tumors with clear cell histology: subject must have progressed after at least one anti-vascular endothelial growth factor receptor (anti-VEGFR) therapy * Tumors with non-clear cell histology must be ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) positive at pre-screening. This sub-group does not have any prior therapy requirement. * Dose expansion cohorts: Histologically confirmed diagnosis of metastatic RCC of either clear cell or papillary histology * Tumors with clear cell histology: subject must have progressed after at least one anti-VEGFR therapy * Tumors with papillary histology: includes unclassified histology with papillary features and must be ENPP3 positive at pre-screening. This sub-group does not have any prior therapy requirement. * Measurable disease according to Response Criteria for Solid Tumors (RECIST Version 1.1) * Eastern Cooperative Group (ECOG) performance status of 0-1 * Hematologic function, as follows: * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L * Platelet count ≥ 100 x 109/L * Hemoglobin ≥ 9 g/dL (transfusions are allowed) * Renal function, as follows: * creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular filtration rate (GFR) \> 50 mL/min if creatinine \> 1.5x ULN * Hepatic function, as follows: * Aspartate aminotransferase (AS…